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Abstract
VEGF inhibition can promote renal vascular and parenchymal injury, causing proteinuria, hypertension and thrombotic
microangiopathy. The mechanisms underlying these side effects are unclear. We investigated the renal effects of the
administration, during 45 days, of sunitinib (Su), a VEGF receptor inhibitor, to rats with 5/6 renal ablation (Nx). Adult male
Munich-Wistar rats were distributed among groups S+V, sham-operated rats receiving vehicle only; S+Su, S rats given Su,
4 mg/kg/day; Nx+V, Nx rats receiving V; and Nx+Su, Nx rats receiving Su. Su caused no change in Group S. Seven and 45
days after renal ablation, renal cortical interstitium was expanded, in association with rarefaction of peritubular capillaries.
Su did not worsen hypertension, proteinuria or interstitial expansion, nor did it affect capillary rarefaction, suggesting little
angiogenic activity in this model. Nx animals exhibited glomerulosclerosis (GS), which was aggravated by Su. This effect
could not be explained by podocyte damage, nor could it be ascribed to tuft hypertrophy or hyperplasia. GS may have
derived from organization of capillary microthrombi, frequently observed in Group Nx+Su. Treatment with Su did not
reduce the fractional glomerular endothelial area, suggesting functional rather than structural cell injury. Chronic VEGF
inhibition has little effect on normal rats, but can affect glomerular endothelium when renal damage is already present.
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Introduction
VEGF is one of the most important proangiogenic factors,
exerting a potent mitogenic activity on endothelial cells [1–4]. In
the kidneys, VEGF is produced predominantly in podocytes, in the
distal tubule and collecting duct, and, to a lesser extent, in the
proximal tubule [5]. In addition to its paracrine effects on the
glomerular endothelium, VEGF produced by podocytes may exert
an autocrine action, substantially influencing the survival and
integrity of the podocyte itself [6].
VEGF inhibition with drugs such as bevacizumab and VEGF-
Trap has been widely used to limit the growth of solid tumors by
restricting their blood supply [7]. In addition, VEGF action can be
inhibited by inactivating the tyrosine kinase domain of its receptors
with broad-spectrum drugs such as sunitinib, sorafenib and
vatalanib [7–9].
Therapies that target VEGF bring a number of adverse effects,
of which proteinuria, hypertension and thrombotic microangio-
pathy are the most commonly observed [10]. However, the
mechanisms involved in the pathogenesis of these toxic effects are
unclear. Reduction of angiogenic activity in the renal parenchyma,
with development or aggravation of tissue hypoxia, may promote
interstitial inflammation [11–13], thus favoring the development
of hypertension [14]. In addition, inhibition of VEGF paracrine
action on the glomerular endothelium may lead to alterations of
the endothelial surface, favoring the development of thrombotic
microangiopathy. Finally, there remains the possibility that the
deleterious effect of VEGF inhibitors may be due to a toxic effect
on podocytes, as a result of the abrogation of the presumed
autocrine action of VEGF [6,15]. The incidence of such adverse
events is extremely variable, depending on the drug used, its
dosage, the underlying disease and duration of treatment, among
several factors [7,10,16]. A possible risk factor facilitating the
development of these side effects is the presence of underlying
renal dysfunction. However, this possibility has not been
examined.
In the present study, we investigated the renal structural and
functional effects of the administration of sunitinib up to 45 days.
Although the effects of this treatment were minimal in normal rats,
the drug promoted significant worsening of the glomerular
changes associated with 5/6 renal ablation, a well-known model
of chronic renal disease.
Results
Mortality was very low in this study, with only one death in the
treated Nx group, and none in the remaining experimental groups.
The results for body weight (BW), TCP, UalbV, SCr and arterial
hematocrit (Ht) 7 and 45 days after renal ablation are presented in
Table 1. All groups gained weight throughout the study. However,
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body growth was slower in both groups of nephrectomized
animals. The S+Su animals exhibited a slight but significant
limitation of body growth at the end of the study. The treatment
with Su did not significantly affect the growth of nephrectomized
animals.
TCP was stable in sham-operated rats throughout the study
(Table 1). By contrast, Nx animals exhibited a progressive
elevation of TCP that was already apparent 7 days after renal
mass removal. Treatment with Su did not aggravate hypertension
in Nx animals. UalbV remained at low levels in sham-operated rats
during the study, and was unaffected by Su treatment (Table 1).
Nx rats exhibited a marked elevation of UalbV with time. Su
treatment of Nx rats promoted no statistical change in UalbV.
SCr remained stable in S rats, and was not affected by Su
treatment (Table 1). In Nx rats, SCr was expectedly elevated
compared to Group S, but remained stable during the study. In
Group Nx+Su, SCr elevation was similar to that in untreated Nx
rats at 7 days, but increased further at 45 days, after renal ablation.
Su treatment did not affect Ht in S rats (Table 1). Ht was
expectedly reduced in untreated Nx at 45 days. Su treatment
promoted an additional decrease in Ht at this time point.
Seven days after renal ablation, Nx rats showed only a small
numerical increase of the fractional cortical interstitial area
(%INT) compared to S (Figure 1A). On Day 45, Nx animals
showed a marked increase in %INT compared to S. No change of
%INT was induced by Su treatment in either S or Nx at any time.
The intensity of macrophage (MØ) infiltration in the renal
cortical interstitium is shown in Figure1B. There was no significant
difference between groups S+V and S+Su. Nx rats exhibited only
a numerical increase of cortical interstitial MØ density 7 days after
renal ablation, compared with their respective controls. At 45
days, Nx rats showed an intense and significant interstitial MØ
infiltration compared with S, as well as with the value observed at
7 days. Su treatment did not alter the density of cortical interstitial
MØ infiltration in Nx animals at any time.
The proliferation of tubular and interstitial cells (Figures 1C and
1D) was similar between S+V and S+Su, at both 7 and 45 days of
treatment. In Nx rats there was a marked increase in the number
of tubular and interstitial PCNA-positive cells at 7 days after renal
ablation. At this time, Su treatment promoted a moderate but
significant reduction of tubular and interstitial proliferation in Nx
rats. At 45 days, the proliferative activity abated in Nx rats, but
remained elevated compared with S. Treatment with Su did not
change this parameter at this point in time.
The area occupied by glomerular endothelium, as assessed by
detection of the JG-12 antigen, is shown in Figure 2A. S+Su rats
showed no difference in the glomerular endothelial area compared
to the respective untreated group. We observed only a numerical
difference between Nx and S rats 7 days after renal ablation.
However, this difference became significant at 45 days, indicating
a progressive loss of glomerular endothelium. Treatment with Su
did not alter significantly the glomerular endothelial area in Nx
animals, at either 7 or 45 days.
The density of peritubular capillaries in the renal cortex,
estimated by quantification of the endothelium-specific JG-12
antigen, decreased progressively in Nx rats (Figure 2B). Treatment
with Su did not result in a significant change of peritubular
vascularization in either S or Nx rats.
On Day 7 after renal ablation, no glomerular abnormalities were
seen in either S+V or S+Su rats, 100% of glomeruli in these groups
being classified as normal (Figure 3A and 3B). This pattern was
maintained at Day 45, despite the presence of rare glomerular
microaneurysms in Group S+Su. At 7 days of treatment, occasional
sclerotic lesions and intracapillary microthrombi, were seen in
a small amount of glomeruli from Groups Nx+V and Nx+Su
(p.0.05 compared to respective controls). The frequency of these
abnormalities was significantly increased on Day 45 (Figures 3C and
3D), especially in Group Nx+Su, in which 7% of glomeruli showed
intracapillary microthrombi (Figure 3E and 3F), most of which
appeared partially organized (Figure 3E), whereas 22% exhibited
segmental or diffuse sclerotic lesions (Figure 3G, p,0.05 NX+Su vs.
Nx+V). Microthrombi were also occasionally observed in the lumen
of renal arterioles in Group Nx+Su (not shown).
No significant difference in glomerular volume was seen
between S and Nx groups 7 days after renal ablation (Figure 4A).
At 45 days, Nx+V exhibited a marked increase in glomerular
volume, in agreement with previous studies. Su treatment
attenuated glomerular hypertrophy, although tuft volume in
Group Nx+Su was still significantly larger than in Group S+V.
The amount of proliferating cells, detected by staining for
PCNA, was much lower in the glomerular tuft than in tubules or
in the cortical interstitium. On Day 7 after renal ablation, no
statistically significant difference in the frequency of glomerular
proliferating cells was seen between S and Nx rats (Figure 4B).
Treatment with Su had no effect in S, but lowered the amount of
PCNA-positive cells in Nx. At 45 days, the extent of cell
proliferation at the glomeruli remained low compared with either
tubules or cortical interstitium. No effect of Su treatment was
detected at this time.
No difference in the percentage of glomerular area staining
positively for ZO-1 was seen between Groups S+V and S+Su, at
either 7 or 45 days after renal ablation (Figure 4C). However, Nx
rats showed a persistent reduction in the glomerular staining for
ZO-1, indicating profound structural changes of podocytes.
Treatment with Su did not result in additional changes of this
parameter, no significant difference being observed between
Groups Nx+V and Nx+Su at either 7 or 45 days of treatment.
The number of podocytes per glomerulus, assessed by the
detection of the WT-1 antigen by immunohistochemistry was
significantly reduced in Group Nx 45 days after renal ablation
(Figure 4D). The number of podocytes per glomerulus was not
affected by treatment with Su in either S rats or Nx rats.
The gene expression of VEGF and of its receptors (VEGFR1,
VEGFR2 and VEGFR3) was assessed by RT-PCR in real time at
7 and 45 days. No difference between S and Nx+V animals was
seen 7 days after renal ablation (Figure 5). However, Nx rats
Table 1. Renal and systemic parameters 7 and 45 days after
renal ablation.
BW TCP UalbV Ht SCr
Day 7 S+V 23962 13662 2.460.5 4761 0.5060.02
S+Su 23863 13961 2.160.4 4461 0.5360.02
Nx+V 20862a 16764a 55.5613.6a 4961 1.1660.04a
Nx+Su 20664a 16563a 53.6610.8a 4661 1.2660.07a
Day 45 S+V 32264c 13962 4.961.4 4861 0.5960.02
S+Su 30165bc 14064 6.863.2 4861c 0.5460.02
Nx+V 25667ac 21164ac 134.1615.1ac 4461c 1.1960.07a
Nx+Su 25067ac 21363ac 149.1614.3ac 3962abc 1.4660.14ab
Mean 61 SE; BW: body weight, grams; TCP: tail-cuff pressure, mmHg; UalbV:
daily urinary albumin excretion rate, mg/24 h; Ht, arterial hematocrit, %; SCr:
serum creatinine concentration, mg/dL. ap,0.05 vs. respective S; bp,0.05 vs.
respective untreated; cp,0.05 vs. respective value on Day 7.
doi:10.1371/journal.pone.0039580.t001
VEGF Blockade in Remnant Kidneys
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treated with Su showed VEGF downregulation in renal tissue at
this time compared to the untreated Nx group. After 45 days, both
Nx+V and Nx+Su rats exhibited a significant reduction in the
renal expression of VEGF and of its receptors, no significant
difference being observed between these two groups. No effect of
Su treatment was seen in S rats.
Figure 1. Evaluation of tubulointerstitial changes. A) Fractional cortical interstitial area; B) Cortical interstitial infiltration by macrophages; C)
Tubular cells in proliferation (PCNA+); D) Interstitial cells in proliferation (PCNA+); ap,0.05 vs. respective S; bp,0.05 vs. respective untreated; cp,0.05
vs. respective value on Day 7.
doi:10.1371/journal.pone.0039580.g001
Figure 2. Vascular endothelial evaluation. A) % glomerular area occupied by endothelium; B) Number of peritubular capillary profiles. ap,0.05
vs. respective S; bp,0.05 vs. respective untreated; cp,0.05 vs. respective value on Day 7.
doi:10.1371/journal.pone.0039580.g002
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Figure 3. Histologic and histomorphometric analysis of glomerular injury (Masson Trichrome). A) and B) normal glomeruli found in
Group S+V and S+Su, respectively; C) and D) representative glomerular sclerotic lesions found in Group Nx+V and Nx+ Su. E) glomerular intracapillary
microthrombi observed in Group Nx+Su, some of which appear partially organized. F) PTAH staining showing the presence of fibrin (in dark purple) in
glomerular capillary lumina of Nx+Su rats. G) distribution of glomerular lesions among ‘‘microthrombi’’ (red) and ‘‘sclerosis’’ (blue). Normal glomeruli
are represented in gray. ap,0.05 vs. respective S; bp,0.05 vs. respective untreated; cp,0.05 vs. respective value on Day 7.
doi:10.1371/journal.pone.0039580.g003
VEGF Blockade in Remnant Kidneys
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Discussion
VEGF is a key element in physiologic and pathologic processes
such as wound healing and neoplastic growth. VEGF contributes
decisively to the homeostasis and survival of endothelial cells,
inhibiting apoptosis even under stressful conditions [17,18].
Adequate VEGF levels are also essential for placental homeo-
stasis and, accordingly, experimental preeclampsia is associated
with low VEGF activity [19]. VEGF is produced by renal
tubular epithelial cells [20,21], and may thus contribute to ensure
adequate supply of oxygen for solute transport. In glomeruli,
VEGF is mostly generated by the podocytes, exerting a crucial
paracrine effect on endothelial cells [15,22]. Accordingly,
administration of VEGF inhibitors as part of antineoplastic
chemotherapy has been associated with the development of
reversible hypertension and proteinuria [7,10,16] and/or glo-
merular microthrombosis [23,24].
Unlike the reports of toxicity after human use of sunitinib, we
found no hypertension, proteinuria or histologically detectable
glomerular damage in sham-operated rats treated with sunitinib
(Group S+Su), which was administered at a similar dose per body
surface as the maximum dose used in humans. These findings are
also apparently in disagreement with those obtained by Kappers,
et al [25], who reported blood pressure elevation in rats treated
with sunitinib. However, it must be noted that these investigators
utilized much higher doses of the drug per m2 of body surface than
employed in the present study and in human subjects.
Despite its lack of effect on blood pressure, sunitinib was not
innocuous when administered to S rats. First, body growth rate
was significantly lower in Group S+Su than in Group S, indicating
that the drug did exert a biological effect. Second, and in
accordance with previous clinical observations [26,27], the
administration of sunitinib to Nx animals resulted in a decrease
in hematocrit, not unexpected considering the known influence of
VEGF on hematopoiesis [28,29] and the low renal expression of
VEGF observed in this group. The lack of effect of Su on blood
pressure or proteinuria was paralleled by an equally undetectable
effect on the density of endothelial cells, either in glomeruli or
peritubular capillaries, at odds with the well-known anti-
angiogenic action of the drug. This finding is in keeping with
the notion that the turnover of endothelial cells is rather low in
normal renal tissue [30,31].
Five-sixths renal ablation represents a context of intense
structural and functional alteration at both the glomeruli and
the renal interstitium. As shown in previous studies [32,33] and
corroborated by the present observations, Nx rats exhibit a peak of
cell proliferation 7 days after renal ablation, which is contributed,
at least in part, by tubular epithelial cells and myofibroblasts [34].
Although some previous studies showed that endothelial cells can
Figure 4. A) Glomerular volume; B) glomerular cell proliferation assessed by the number of PCNA+ cells; C) Percentage of
glomerular area staining positively for ZO-1; D) Number of podocytes per glomerulus. ap,0.05 vs. respective S; bp,0.05 vs. respective
untreated; cp,0.05 vs. respective value on Day 7.
doi:10.1371/journal.pone.0039580.g004
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also contribute to this initial proliferative surge [30,31], we
observed, as early as 7 days after renal ablation, a modest but
significant reduction in the density of cells staining positively for
the JG-12 antigen, specific for vascular endothelial cells. This
observation is consistent with our finding that the renal expression
of VEGF, as well as of its receptors, was diminished in Nx rats at
this time, corroborating previous findings [30,35,36] and suggest-
ing that the participation of endothelial cells in the intense
proliferative activity observed at this early stage is rather limited.
Also in accordance with previous studies [30,31], peritubular
capillary density was progressively rarefied in Nx rats, which may
have contributed, along with the observed distortion of the
interstitial architecture, to the development of tissue hypoxia and
the progression of renal injury [37].
Chronic treatment with Su promoted a modest reduction in
interstitial cell proliferation 7 days after ablation. However, it is
unlikely that this finding reflects a specific antiproliferative effect of
Su treatment on endothelial cells, since the density of peritubular
capillaries in Group Nx+Su never differed significantly from that
observed in untreated Nx rats, indicating that the impairment of
the renal microcirculation by renal ablation was not aggravated by
the drug. Accordingly, Su treatment did not worsen renal
interstitial expansion/inflammation in Nx rats. In addition, Su
treatment affected neither the renal expression of VEGF nor that
of its receptors. Together, these observations indicate that chronic
Su treatment of Nx rats had little impact on the tubulointerstitial
perfusion or on the extent of structural damage to the renal
interstitium. However, we cannot exclude the possibility that
a significant effect of Su treatment on these parameters would be
seen if a longer period of observation were feasible.
In contrast with its little effect on the renal interstitium, Su
treatment exerted a considerable impact on the glomeruli of Nx
rats, in which a marked increase in the frequency of sclerotic
lesions was observed 45 days after renal ablation. The
mechanisms involved in the exacerbation of glomerulosclerosis
by Su are not immediately apparent. Mechanical stress, caused
by glomerular hypertension and/or glomerular hypertrophy,
plays an important role in the pathogenesis of progressive
glomerulosclerosis [38,39]. Glomerular tuft volume was indeed
increased in Nx rats. Su treatment of these animals did not
increase glomerular volume at 7 days, and even attenuated tuft
hypertrophy at the end of the experimental protocol. These
findings are in keeping with those obtained in Nx [40] and
uninephrectomized [41] rats by neutralizing VEGF activity. The
possibility that the deleterious effect of Su was due to
exacerbation of intraglomerular hypertension, a well-known
factor of glomerular injury, cannot be excluded, since glomerular
hydraulic pressure was not measured in this study. However, this
explanation seems unlikely, since glomerular hypertension and
glomerular hypertrophy are invariably associated in the Nx
Figure 5. RT-PCR analysis of the expression of VEGF (A) and of its receptors, VEGFR1 (B), VEGFR2 (C), and VEGFR3 (D). ap,0.05 vs.
respective S; bp,0.05 vs. respective untreated; cp,0.05 vs. respective value on Day 7.
doi:10.1371/journal.pone.0039580.g005
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model [33,38,39,42]. A possible exacerbation of glomerular
hyperplasia is also unlikely, given that Su treatment did not alter
the rate of cell proliferation in the glomerular tuft, and even
reduced it on Day 7. The latter effect may have resulted from
a possible action of Su on mesangial PDGF receptors [9], which
are known to stimulate glomerular cell proliferation [32] and to
promote progressive glomerular injury [43]. Since sunitinib
treatment accelerated glomerulosclerosis, rather than ameliorat-
ing glomerular injury, any renoprotection that might have been
afforded by PDGF inhibition must have been surpaseded by the
effect of the drug on VEGF receptors.
Podocyte loss or injury is one of the possible mechanisms
underlying the development of glomerulosclerosis in renal mass
removal models [44,45]. In the present study, the number of
podocytes was clearly diminished in Nx rats, as evidenced by the
progressive decrease, compared with Sham rats, of the glomerular
content of the WT-1 antigen, while the deficiency of ZO-1
indicates that the connection between podocytes and the integrity
of the slit membrane, hence the structure of the glomerular
visceral epithelial layer, were compromised in these animals.
Podocyte damage in the Nx model may be due to mechanical
stress from glomerular hypertension and/or hypertrophy. Addi-
tional injury may result from the declining renal levels of VEGF in
these rats, since VEGF, which is mainly produced by podocytes
[20,46], may exert a trophic autocrine effect on these cells [6,47].
However, administration of Su to Nx rats, caused no additional
damage to these cells, as indicated by the little effect on
albuminuria, and by the lack of further changes in the renal
content of WT-1 or ZO-1 in Group Nx+Su. These findings lend
no support to the concept that VEGF exerts a vital autocrine effect
on podocytes, and indicate that the aggravation of GS by Su
treatment cannot be explained by an exacerbation of podocyte
injury. Accordingly, these results are consistent with recent
observations, in mice with podocyte-specific deletion of the
VEGFR-2 receptor, that a VEGF-VEGFR2 interaction is absent
in podocytes [22].
Abundant evidence now indicates that VEGF, through its
binding to VEGFR2, exerts a paracrine effect on the glomerular
endothelium, which is crucial to the proliferation, differentiation
and survival of these cells [15,22,48]. Abrogation of this trophic
effect may help to explain the glomerular changes associated with
the use of anti-angiogenic therapies based on VEGF inhibition
[10,23,49] and reproduced in studies in which targeted silencing
of the VEGF gene was specifically performed in podocytes [23].
These adverse effects consist mostly of proteinuria and hyper-
tension [7,10]. However, the formation of microthrombi in
glomerular capillaries is also frequently observed in patients
treated with VEGF inhibitors and in experimental studies of
specific deletion of the VEGF gene, suggesting damage to the
vascular endothelium [23,24,49]. The presence of focal segmen-
tal glomerulosclerosis has occasionally been demonstrated in
these patients [49,50]. Nevertheless, we were unable to detect the
presence of microthrombi in sunitinib-treated sham-operated
rats, although a few glomerular microaneurysms were observed
in these animals.
Nx rats exhibited a decline in the area occupied by glomerular
endothelium. This finding, which corroborates previous observa-
tions [30], may result from mechanical stress caused by glomerular
hypertension and hypertrophy, and/or from the decreased renal
expression of VEGF, observed in this study as well as in other
studies of the Nx model [30,35]. Damage and/or loss of
endothelial cells likely explain the presence of microthrombi in
Nx rats, which affected about 2% of the examined glomeruli.
Blockade of VEGF receptors with sunitinib exacerbated the
formation of glomerular microthrombi, the frequency of which
nearly tripled. Since sunitinib treatment promoted no additional
loss of glomerular endothelial cells in Nx rats, formation of
microthrombi may reflect functional changes of the endothelial
cells, as suggested by previous studies [23,24,49,50], resulting in
alteration of their surface and facilitating platelet adhesion.
Organization of microthrombi, suggested by the present histologic
observations, may explain the aggravation of glomerulosclerosis in
sunitinib-treated Nx rats in the absence of additional podocyte
damage or exacerbation of proteinuria.
An unexpected finding of this study was that the expression of
both VEGF and of its main receptors was downregulated in the
renal tissue of Nx rats. The reason for this finding is unknown.
VEGFR2 has been demonstrated to be absent in podocytes [22]
and, accordingly, sunitinib had little effect on these cells. These
observations indicate that any effect of the drug on VEGF
production must have taken place outside the glomeruli, that is, in
tubules and/or pericytes. However, any mechanistic interpretation
of these findings is necessarily speculative before further data
becomes available.
In summary, the results of the present study suggest that VEGF
inhibition by sunitinib does not cause gross alterations in the
glomerular endothelium or in the renal structure of normal rats.
However, when nephron number is reduced, the action of the
drug may add to that of other pathogenic factors such as
glomerular hemodynamic stress, promoting glomerular changes
that culminate in the formation of intracapillary microthrombi.
Functional changes of the glomerular endothelium, with sub-
sequent organization of microthrombi, may explain the worsening
of glomerulosclerosis observed in animals treated with the drug,
although the present data do not warrant a firm conclusion in this
regard. Renal ablation resulted in progressive capillary rarefaction
at the cortical interstitium. Administration of Su did not aggravate
tubulointerstitial fibrosis or the loss of peritubular capillaries in Nx
rats, indicating that the degree of compensatory angiogenesis must
be low in this model.
Materials and Methods
Experimental Groups
Adult male Munich-Wistar rats (n = 151), weighing 220–260 g,
obtained from a local facility at the Faculty of Medicine,
University of Sa˜o Paulo, were used in this study. Five-sixths renal
ablation (Nx) was performed in a single step procedure after
ventral laparotomy under anesthesia with ketamine 50 mg/kg and
xylazine 10 mg/kg im. The right kidney was removed and two
branches of the left renal artery were ligated, resulting in the
infarction of two-thirds of the left kidney. The whole operation
lasted about 30 minutes. Sham-operated rats underwent anesthe-
sia and manipulation of the renal pedicles, without any removal of
renal mass. Rats were then returned to their cages and were fully
recovered and active three hours after surgery. All animals were
given free access to tap water, fed regular rodent chow containing
0.5 Na and 22% protein (Nuvital Labs, Curitiba, Brazil), and kept
at 2361uC and 6065% relative air humidity, under an artificial
12–12 hour light/dark cycle. All experimental procedures were
specifically approved by the local Research Ethics Committee
(Comissa˜o de E´tica para Ana´lise de Projetos de Pesquisa do
Hospital das Clı´nicas da Faculdade de Medicina da Universidade
de Sa˜o Paulo, CAPPesq under process nu 0166/07), and
developed in strict conformity with our institutional guidelines
and with international standards for manipulation and care of
laboratory animals.
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Experimental Groups
Sunitinib treatment was started on the day after renal ablation.
The drug was dissolved in carboxymethylcellulose 0.5% at
a concentration of 2 mg/mL and 2 mL/kg of this solution was
administered by gavage once daily, so as to achieve a dosage of
4 mg/kg/day. Sham and Nx rats were distributed among four
groups: S+V, sham-operated rats receiving vehicle (carboxymeth-
ylcellulose) only (N = 31); S+Su, sham-operated rats receiving
sunitinib as described earlier (N = 32); Nx+V, Nx rats treated with
vehicle only (N = 43); and Nx+Su, Nx rats treated with sunitinib as
detailed above (N = 45).
Renal Morphology Evaluation
At either 7 or 45 days of treatment, 24-h urine was obtained for
assessment of albumin (UalbV) by radial immunodiffusion. The
tail-cuff pressure (TCP) was measured using an optoelectronic
automated device (Visitech Systems, Apex, NC), under light
restraining and after light warming. To avoid any interference of
stress, all rats were preconditioned to the procedure, and were
invariably calm at the time of TCP determination. In addition,
blood pressure evaluation was always performed after stabilization,
that is, TCP was taken as the average of at least three consecutive
measurements that varied by no more than 2 mmHg. Rats were
then anesthetized with ketamine, 50 mg/kg and xylazine 10 mg/
kg im, and a 1-mL blood sample was collected from the abdominal
aorta for measurement of hematocrit and serum creatinine
concentration (SCr). The kidneys were then retrogradely perfu-
sion-fixed through the abdominal aorta with Dubosq-Brazil
solution after a brief washout with saline to remove blood from
the renal vessels. After weighing, two midcoronal renal slices were
postfixed in buffered 4% formaldehyde and embedded in paraffin
using conventional sequential techniques. Histomorphometric and
immunohistochemical analyses of the renal tissue were performed
in 4-mm-thick sections.
Histomorphometric Analysis
All histomorphometric evaluations were performed in Masson
trichrome-stained sections by a single observer who was blinded to
the experimental groups. The frequency of glomerulosclerotic
lesions and microthrombi was determined in at least 60 glomeruli
per rat (.100 in over 90% of all animals). The fraction of the renal
cortical area occupied by interstitial tissue (%INT), used as
a measure of the degree of interstitial expansion, was estimated by
a point counting technique [51]. The presence of fibrin in the
lumina of glomerular capillaries was detected by staining with
phosphotungstic acid hematoxylin (PTAH).
Mean glomerular random cross sectional area (AG) was
determined by averaging individual values for 25 consecutive
glomerular tuft profiles using an image processing software (Image
Pro PlusH, version 7.01). The average glomerular tuft volume (VG)
for each rat was then calculated as VG = 1.25 (AG)
3/2 [52].
Immunohistochemical Analysis
Immunohistochemistry was performed on 4-mm-thick sections,
mounted on glass slides precoated with 2% silane. Sections were
deparaffinized and rehydrated by conventional techniques, then
heated in citrate buffer for antigen retrieval and incubated
overnight with the primary antibody at 4uC. For the negative
control experiments, incubation with the primary antibody was
omitted. The following primary antibodies were used: monoclonal
mouse anti-rat ED-1 antibody (for macrophage detection; Serotec,
Oxford, United Kingdom); monoclonal mouse anti-rat proliferat-
ing cell nuclear antigen (PCNA) (Dako, Glostrup, Denmark);
monoclonal mouse anti-rat endothelial aminopeptidase P (JG-12)
(Bender MedSystems, California, USA); polyclonal rabbit anti-
human zonula occludens-1 (ZO-1) (Zymed, San Francisco, USA);
and monoclonal mouse anti-human Wilms’ tumor 1 (WT-1)
(Dako, Glostrup, Denmark).
For ED-1 detection, sections were preincubated with 5%
normal rabbit serum to prevent nonspecific binding, then
incubated overnight at 4uC with the primary antibody, diluted
in bovine serum albumin (BSA) at 0.5%. After rinsing with Tris-
buffered saline (TBS), sections were incubated with a 2% solution
of rabbit anti-mouse immunoglobulin (Dako, Glostrup, Denmark)
in BSA, then with an alkaline phosphatase anti-alkaline phospha-
tase (APAAP) complex (Dako, Glostrup, Denmark). Sections were
then developed with a fast-red dye solution (Sigma-Aldrich, Saint
Louis, MO). For detection of all other antigens, sections were
pretreated with 30% hydrogen peroxide in methanol and
preincubated with normal horse serum diluted in 2% non fat
milk. The primary antibodies were also diluted in 2% non fat milk.
The Envision System (Dako, Glostrup, Denmark) was used for
PCNA detection, whereas the NovoLink Polymer Detection
System (Novocastra, Benton Lane, United Kingdom) was utilized
for the remaining antigens. Sections were developed with DAB
substrate (Dako, Glostrup, Denmark).
All slices were counterstained with Mayer’s hemalaum and
covered with a glycerin-gelatin mixture.
The renal density of macrophages and proliferating cells was
evaluated in a blinded manner at6200 magnification. For each
section, 25 microscopic fields (corresponding to a total area of
1.6 mm2) were examined. The percentage of glomerular area
staining positively for ZO-1 or JG-12 was evaluated with an image
processing software (Image Pro PlusH, version 7.01). The number
of podocytes per glomerular tuft was assessed in 25 glomeruli per
rat under 4006 magnification. Peritubular capillaries were
counted in 25 consecutive microscopic fields under a 2006
magnification and expressed as the number of capillary profiles
per mm2 of cortical tissue.
Gene Expression
Renal tissue was collected at 7 and 45 days, being quickly frozen in
liquid nitrogen. Total RNA was isolated using TRIzol Reagent
(Invitrogen, Carlsbad, USA), and RNA concentrations were de-
termined by Nanodrop (ND-1000 UV-Vis). First-strand cDNAs
were synthesized using the MML-V reverse transcriptase (Invitro-
gen, Carlsbad, USA). Reverse transcription-polymerase chain
reaction (RT-PCR) for VEGF-A (Rn 00582935_m1) and for HPRT
(Rn01527838_g1) was performed using TaqMan probes (Applied
Biosystems, Foster City, USA) at ABI PRISM 7300 Sequence
Detector, using Sequence Detection Software 1.9 for analysis
(Applied Biosystems, Foster City, USA). The following primers were
designed based on a known sequence of nucleobases in GenBank,
being adapted for the PCR technique by Primer Express software
(Applied Biosystems, Foster City, USA): for VEGFR1/Flt1 sense 59-
GACAAGGGACTCTACACTTGTCGT-39, antisense 59-
CGATGCTTCACGCTGATAAATCCC-39; for VEGFR2/Flk1
sense 59-ACTACACGGTCATCCTCACCAATC-39, antisense 59-
AGGAGAGATCAAGGCTTTCTCACC-39; for VEGFR3/Flt4
sense 59- AAGGAAGCTTCTTCACCCAGCATC-39, antisense 59-
GGCAAATGTCTTACAGGGTGTCCA-39. For PCR Real
Time amplification, Mix TaqMan (Applied Biosystems, Foster
City, USA), or SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, USA) were used. Cycling conditions for SYBR primers
were 10 min at 95uC followed by 45 cycles of 20 sec at 95uC and
20 sec at 60uC. mRNA expression was normalized to HPRT
(housekeeping gene) abundance. The Ct (threshold cycle) for the
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target gene and the Ct for the internal control were determined for
each sample and the relative mRNA expression was calculated by
the 22DDCT method. All RT-PCR experimental results are
expressed as an n-fold difference relative to the calibrator. All
samples were analyzed in triplicate.
Statistical Analysis
Statistical differences were assessed by two-way ANOVA, with
treatment and time as intervening factors and with pairwise
posttest comparisons according to the Bonferroni method [53].
Gene expression results were assessed by one-way ANOVA with
pairwise posttest comparisons according to the Bonferroni method
[53]. Results are expressed as Mean 6 SE.
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